What to Expect From Cencora's Q4 2025 Earnings Report

Core Insights - Cencora, Inc. is a leading global healthcare solutions provider with a market cap of $63.8 billion, focusing on sourcing and distributing pharmaceutical and healthcare products while offering logistics, data analytics, and commercialization services [1] Financial Performance - Cencora is expected to announce its fiscal Q4 2025 results on November 5, with analysts forecasting an adjusted EPS of $3.79, representing a 13.5% increase from $3.34 in the same quarter last year [2] - For fiscal 2025, the projected adjusted EPS is $15.93, reflecting a 15.8% increase from $13.76 in fiscal 2024 [3] Stock Performance - Cencora's shares have increased by over 39% in the past 52 weeks, outperforming the S&P 500 Index's rise of 15.1% and the Health Care Select Sector SPDR Fund's decline of 4.1% during the same period [4] Recent Results and Challenges - In Q3 2025, Cencora reported an adjusted EPS of $4 and revenue of $80.66 billion, but shares fell by 2.9% due to a 12.9% decline in operating income from the International Healthcare Solutions segment, increased interest expenses of $81.8 million (up $50.5 million), and a 17.3% rise in operating expenses [5] Analyst Ratings - The consensus rating for Cencora's stock is bullish, with a "Strong Buy" rating from 11 out of 15 analysts, while four analysts recommend a "Hold" rating. The average price target is $339.71, indicating a potential upside of 3.3% from current levels [6]